SCHEMBL8486170

SCHEMBL8486170

Cc1ccnc(C(=O)NC(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSA P10619 2/20 0.54
KDM4C Q9H3R0 1/20 0.51
CNR1 P21554 1/20 0.49
ANO1 Q5XXA6 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TSHR P16473 1/20 0.46
PARP1 P09874 1/20 0.45
FDPS P14324 2/20 0.44
GRM5 P41594 2/20 0.44
CHRM2 P08172 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
CSF1R P07333 1/20 0.42
FLT3 P36888 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161556 0.83 KDM4C (0.51) CTSAKDM4CCNR1ANO1NPC1
SCHEMBL178048 0.81 KDM4C (0.75) KDM4CANO1NPC1RAB9ATSHR
SCHEMBL25820328 0.81 KDM4C (0.50) KDM4CCNR1ANO1NPC1RAB9A
SCHEMBL29580736 0.80 CTSA (0.48) CTSACNR1NPC1RAB9AFDPS
SCHEMBL171083 0.80 CTSA (0.48) CTSACNR1NPC1RAB9AFDPS
SCHEMBL25832636 0.79 CTSA (0.57) CTSAKDM4CANO1NPC1RAB9A
SCHEMBL107759 0.79 CTSA (0.50) CTSANPC1RAB9AFDPSGRM5
SCHEMBL19249060 0.78 GRM5 (0.50) KDM4CANO1NPC1RAB9ATSHR
SCHEMBL131790 0.77 ALDH1A1 (0.51) KDM4CALDH1A1SMN1; SMN2TP53
SCHEMBL16689553 0.77 UHRF1 (0.43) CTSAKDM4CFDPSCSF1RFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 US disclosed
US-6005112-A REACTING SUBSTITUTED OR UNSUBSTITUTED PYRIDINE METAL COMPOUND WITH SUBSTITUTED ISOCYANATE OR ISOTHIOCYANATE KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1999-12-21 US disclosed
EP-0881217-A1 PROCESS FOR PRODUCING PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1998-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION GCGR, STUB1, GID4 CTSA 3371/4885KDM4C 956/4885CNR1 3288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.